Prenuvo and UT Dallas researchers found links between sleep efficiency, visceral fat and brain volume, with long sleepers ...

Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...

Swiss fertility heavyweight bets on stem-cell-derived egg maturation – and on ovarian biology as a market worth owning.

Arrowhead says its RNAi drug crossed the blood-brain barrier in healthy volunteers and sharply lowered tau, a protein tied to Alzheimer’s.

Berlin keynote details Eos SENOLYTIX's pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan.

The Boston company says the deal more than doubles its patient reach and opens a path to brain-based sleep testing in primary care from 2027.

United Therapeutics will test treprostinil SMI in about 40 patients with pulmonary hypertension linked to COPD.

XellSmart’s off-the-shelf XS411 lifted motor scores in nine patients, and its 30-person Phase II trial has finished enrolling ...

As pharma shops for de-risked science, venture money is moving later and concentrating in fewer, bigger bets – our report ...

TimePie's Hebe Chen spotlights key developments from Shanghai, from therapeutic targets to China’s expanding clinical ...

German biotech MODAG won for pairing a CE-marked diagnostic with a drug candidate that targets the same protein.

Decades founder Eva Novak on why the blue zone idea can survive scrutiny, but only if validation becomes independent, open and repeated. In early October, a mountain village in central Sardinia was ...